financetom
Business
financetom
/
Business
/
Centerra Gold Q3 profit beats estimates on robust margins 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Centerra Gold Q3 profit beats estimates on robust margins 
Oct 28, 2025 2:31 PM

Overview

* Centerra Q3 revenue and adjusted EPS beat analyst expectations, per LSEG data

* Company generated $98.7 mln in free cash flow, driven by strong operational performance

* Cash balance increased to $562 mln, supporting strategic investments and shareholder returns

Outlook

* Centerra expects Goldfield project first production by end of 2028

* Company plans to complete Kemess PEA in Q1 2026

* Centerra intends to renew NCIB for share repurchases

Result Drivers

* ÖKSÜT PERFORMANCE - Higher-than-expected grades at Öksüt boosted gold production, contributing to strong quarterly results

* MOUNT MILLIGAN CHALLENGES - Complex mineralization at Mount Milligan led to lower gold grades, but production remained aligned with expectations

* ELEVATED METAL PRICES - Elevated metal prices supported robust margins and free cash flow generation

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $395.20 $319.10

Revenue mln mln (2

Analysts

)

Q3 Beat $0.33 $0.16 (6

Adjusted Analysts

EPS )

Q3 EPS $1.44

Q3 Beat $66.40 $49.60

Adjusted mln mln (1

Net Analyst)

Income

Q3 Net $292.20

Income mln

Q3 Free $98.70

Cash mln

Flow

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the gold peer group is "buy."

* Wall Street's median 12-month price target for Centerra Gold Inc ( CGAU ) is C$15.50, about 2.3% above its October 27 closing price of C$15.15

* The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
QVC Group Q3 revenue down on lower shipping units
QVC Group Q3 revenue down on lower shipping units
Nov 5, 2025
Overview * QVC Group ( QVCGA ) Q3 revenue decreased 6% yr/yr, driven by declines in QxH and Cornerstone * Operating income fell 61% yr/yr, pressured by tariffs and revenue decline * Adjusted OIBDA decreased 32% yr/yr due to higher marketing costs and sales deleverage Result Drivers * QxH REVENUE DECLINE - Driven by a 7% decrease in units shipped...
Compass Therapeutics Q3 net loss widens to $14.3 mln
Compass Therapeutics Q3 net loss widens to $14.3 mln
Nov 5, 2025
Overview * Compass Therapeutics ( CMPX ) reports Q3 net loss of $14.3 mln, increased R&D expenses * Company holds $220 mln in cash, providing runway into 2028 * New response observed in CTX-8371 Phase 1 study, no dose-limiting toxicities Outlook * Compass expects to report OS and PFS data for tovecimig in late Q1 2026 * CTX-8371 topline data...
Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast
Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast
Nov 5, 2025
Nov 5 (Reuters) - Cencora ( COR ) will invest over $1 billion through 2030 to expand its U.S. network, the drug distributor said on Wednesday, after forecasting adjusted profit for next year above Wall Street expectations. The company said it will build a second national distribution center in Harrison, Ohio, and new or enlarged sites in California and Alabama....
Inogen Q3 revenue beats estimates
Inogen Q3 revenue beats estimates
Nov 5, 2025
Overview * Inogen Q3 revenue grows 4% yr/yr, beating analyst expectations * Adjusted EBITDA for Q3 beats analyst estimates, reflecting improved operational performance * Company reiterates full-year revenue guidance, raises adjusted EBITDA outlook Outlook * Inogen reiterates full-year revenue guidance of $354 mln to $357 mln * Company raises full-year adjusted EBITDA guidance to approximately $2 mln * Inogen expects...
Copyright 2023-2026 - www.financetom.com All Rights Reserved